SEARCH
検索詳細
中村 浩之 (ナカムラ ヒロユキ)
| 北海道大学病院 内科 | 助教 |
研究者基本情報
■ URLresearchmap URLホームページURL■ ID 各種
研究者番号
- 30832357
研究活動情報
■ 論文- Investigation of Lysosome-Associated Membrane Protein 3 Highlights the Role of Lysosome in Pathophysiology and Treatment of Sjögren's Disease.
Hiroyuki Nakamura; Tsutomu Tanaka; Masayuki Noguchi; Tatsuya Atsumi; Blake M Warner; John A Chiorini
Arthritis & rheumatology (Hoboken, N.J.), 2025年08月04日, [国際誌]
英語, 研究論文(学術雑誌), Lysosome-associated membrane protein 3 (LAMP3) is a unique lysosomal membrane protein specifically expressed in mature dendritic cells and type II pneumocytes. Its ectopic expression in salivary gland epithelial cells (SGECs) is induced by type I interferon (IFN) signaling and further amplified through Toll-like receptor 7 (TLR7) activation, which is implicated in the pathogenesis of Sjögren's disease (SjD). This aberrant upregulation disrupts glandular function by promoting endolysosomal degradation of aquaporin 5 (AQP5) and Na-K-Cl cotransporter-1, leading to impaired fluid secretion and associated clinical sequelae (e.g., dry mouth). Additionally, LAMP3-mediated lysosomal exocytosis of damage-associated molecular patterns enhances monocytic bone morphogenetic protein 6 (BMP6) production, which in turn suppresses AQP5 transcription. Moreover, LAMP3 drives the extracellular vesicle-mediated release of autoantigens, which further amplifies autoimmunity, and lysosome-dependent cell death in SGECs contributes to tissue damage. These findings establish LAMP3 as a pivotal regulatory hinge in SjD pathogenesis, linking IFN-TLR7 signaling, lysosomal dysfunction, and glandular hypofunction. Its central role makes it a compelling therapeutic target, with strategies including IFN and TLR7 pathway inhibitors to limit its induction, restoration of lysosomal function, BMP6 inhibition to preserve AQP5 expression, and aquaporin gene therapy to improve fluid secretion. - A Frameshift Mutation of NLRP12 in a Patient With Chronic Recurrent Multifocal Osteomyelitis.
Koki Nakamura; Hiroyuki Nakamura; Masatoshi Kanda; Hiroki Takahashi
The Journal of rheumatology, 52, 7, 735, 737, 2025年07月01日, [国際誌]
英語, jrheum;52/7/735/UF10520735F1uf1-0520735. - Cat whiskers on the hip: a case of sarcoid myopathy.
Koki Nakamura; Masatoshi Kanda; Hiroyuki Nakamura; Hiroki Takahashi
QJM : monthly journal of the Association of Physicians, 118, 4, 284, 285, 2025年04月01日, [国際誌]
英語, 研究論文(学術雑誌) - Case Report: Severe Immune-Related Adverse Event Under Pembrolizumab Therapy for Discoid Lupus Erythematosus-Related Squamous Cell Carcinoma.
Hidenori Amaike; Hiroyuki Nakamura; Koki Nakamura; Ken Nagahata; Kohei Horimoto; Junji Kato; Masatoshi Kanda; Shintaro Sugita; Hisashi Uhara; Hiroki Takahashi
International journal of rheumatic diseases, 28, 2, e70108, 2025年02月, [国際誌]
英語 - Paravertebral Soft Tissue Shadows on a Chest Radiograph.
Koki Nakamura; Ken Nagahata; Hiroyuki Nakamura; Hiroki Takahashi
International journal of rheumatic diseases, 27, 12, e70005, 2024年12月, [国際誌]
英語, 研究論文(学術雑誌) - Plasma amino acid concentration in patients with IgG4-related disease.
Hiroyuki Nakamura; Masatoshi Kanda; Hidenori Amaike; Ken Nagahata; Hiroki Takahashi
Clinical and experimental rheumatology, 42, 9, 1884, 1885, 2024年09月, [国際誌]
英語 - Amplified Type I Interferon Response in Sjögren's Disease via Ectopic Toll-Like Receptor 7 Expression in Salivary Gland Epithelial Cells Induced by Lysosome-Associated Membrane Protein 3.
Hiroyuki Nakamura; Tsutomu Tanaka; Changyu Zheng; Sandra A Afione; Tatsuya Atsumi; Masayuki Noguchi; Fabiola Reis Oliveira; Ana Carolina F Motta; Fernando Chahud; Eduardo M Rocha; Blake M Warner; John A Chiorini
Arthritis & rheumatology (Hoboken, N.J.), 76, 7, 1109, 1119, 2024年07月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Lysosome-associated membrane protein 3 (LAMP3) misexpression in salivary gland epithelial cells plays a causal role in the development of salivary gland dysfunction and autoimmunity associated with Sjögren's disease (SjD). This study aimed to clarify how epithelial LAMP3 misexpression is induced in SjD. METHODS: To explore upstream signaling pathways associated with LAMP3 expression, we conducted multiple RNA sequencing analyses of minor salivary glands from patients with SjD, submandibular glands from a mouse model of SjD, and salivary gland epithelial cell lines. A hypothesis generated by the RNA sequencing analyses was further tested by in vitro and in vivo assays with gene manipulation. RESULTS: Transcriptome analysis suggested LAMP3 expression was associated with enhanced type I interferon (IFN) and IFNγ signaling pathways in patients with SjD. In vitro studies showed that type I IFN but not IFNγ stimulation could induce LAMP3 expression in salivary gland epithelial cells. Moreover, we discovered that LAMP3 overexpression could induce ectopic Toll-like receptor 7 (TLR-7) expression and type I IFN production in salivary gland epithelial cells both in vitro and in vivo. TLR-7 knockout mice did not develop any SjD-related symptoms following LAMP3 induction. CONCLUSION: Epithelial LAMP3 misexpression can be induced through enhanced type I IFN response in salivary glands. In addition, LAMP3 can promote type I IFN production via ectopic TLR-7 expression in salivary gland epithelial cells. This positive feedback loop can contribute to maintaining LAMP3 misexpression and amplifying type I IFN production in salivary glands, which plays an essential role in the pathophysiology of SjD. - Case report: Lymphocyte-variant hypereosinophilic syndrome with dense IgG4-positive plasma cell infiltration of lymph nodes.
Hidenori Amaike; Ken Nagahata; Masatoshi Kanda; Hiroyuki Nakamura; Hiromi Fujita; Hiroaki Shima; Yasuharu Sato; Hiroki Takahashi
International journal of rheumatic diseases, 27, 6, e15206, 2024年06月, [国際誌]
英語 - Successful treatment of ANCA-associated glomerulonephritis following pulmonary alveolar proteinosis by rituximab and avacopan.
Masanari Sugawara; Arata Osanami; Yuichiro Asai; Yayoi Ogawa; Ken Nagahata; Hiroyuki Nakamura; Chisako Suzuki; Masatoshi Kanda; Hiroki Takahashi
Rheumatology (Oxford, England), 63, 2, e51-e52, 2024年02月01日, [国際誌]
英語, 研究論文(学術雑誌) - Case report: Autoinflammatory manifestations in a patient with Sjögren's disease.
Hiroyuki Nakamura; Ken Nagahata; Hidenori Amaike; Masatoshi Kanda; Hiroki Takahashi
International journal of rheumatic diseases, 27, 2, e15083, 2024年02月, [国際誌]
英語 - Lysosome-Associated Membrane Protein 3 Induces Lysosome-Dependent Cell Death by Impairing Autophagic Caspase 8 Degradation in the Salivary Glands of Individuals With Sjögren's Disease.
Hiroyuki Nakamura; Tsutomu Tanaka; Changyu Zheng; Sandra A Afione; Blake M Warner; Masayuki Noguchi; Tatsuya Atsumi; John A Chiorini
Arthritis & rheumatology (Hoboken, N.J.), 75, 9, 1586, 1598, 2023年09月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Lysosome-associated membrane protein 3 (LAMP3) overexpression is implicated in the development and progression of Sjögren's disease (SjD) by inducing lysosomal membrane permeabilization (LMP) and apoptotic cell death in salivary gland epithelium. The aim of this study was to clarify the molecular details of LAMP3-induced lysosome-dependent cell death and to test lysosomal biogenesis as a therapeutic intervention. METHODS: Human labial minor salivary gland biopsies were analyzed using immunofluorescence staining for LAMP3 expression levels and galectin-3 puncta formation, a marker of LMP. Expression level of caspase 8, an initiator of LMP, was determined by Western blotting in cell culture. Galectin-3 puncta formation and apoptosis were evaluated in cell cultures and a mouse model treated with glucagon-like peptide 1 receptor (GLP-1R) agonists, a known promoter of lysosomal biogenesis. RESULTS: Galectin-3 puncta formation was more frequent in the salivary glands of SjD patients compared to control glands. The proportion of galectin-3 puncta-positive cells was positively correlated with LAMP3 expression levels in the glands. LAMP3 overexpression increased caspase 8 expression, and knockdown of caspase 8 decreased galectin-3 puncta formation and apoptosis in LAMP3-overexpressing cells. Inhibition of autophagy increased caspase 8 expression, while restoration of lysosomal function using GLP-1R agonists decreased caspase 8 expression, which reduced galectin-3 puncta formation and apoptosis in both LAMP3-overexpressing cells and mice. CONCLUSION: LAMP3 overexpression induced lysosomal dysfunction, resulting in lysosome-dependent cell death via impaired autophagic caspase 8 degradation, and restoring lysosomal function using GLP-1R agonists could prevent this. These findings suggested that LAMP3-induced lysosomal dysfunction is central to disease development and is a target for therapeutic intervention in SjD. - LAMP3 transfer via extracellular particles induces apoptosis in Sjögren's disease.
Tsutomu Tanaka; Hiroyuki Nakamura; Duy T Tran; Blake M Warner; Yan Wang; Tatsuya Atsumi; Masayuki Noguchi; John A Chiorini
Scientific reports, 13, 1, 2595, 2595, 2023年02月14日, [国際誌]
英語, 研究論文(学術雑誌), Sjögren's disease (SjD) is an autoimmune disease that affects exocrine tissues and is characterized by increased apoptosis in salivary and lacrimal glands. Although the pathogenic mechanism triggering SjD is not well understood, overexpression of lysosome-associated membrane protein 3 (LAMP3) is associated with the disease in a subset of SjD patients and the development of SjD-like phenotype in mice. In this study, histological analysis of minor salivary glands of SjD patients suggested that LAMP3-containing material is being ejected from cells. Follow-on in vitro experiments with cells exposed to extracellular particles (EPs) derived from LAMP3-overexpressing cells showed increased apoptosis. Proteomics identified LAMP3 as a major component of EPs derived from LAMP3-overexpressing cells. Live-cell imaging visualized release and uptake of LAMP3-containing EPs from LAMP3-overexpressing cells to naïve cells. Furthermore, experiments with recombinant LAMP3 protein alone or complexed with Xfect protein transfection reagent demonstrated that internalization of LAMP3 was required for apoptosis in a caspase-dependent pathway. Taken together, we identified a new role for extracellular LAMP3 in cell-to-cell communication via EPs, which provides further support for targeting LAMP3 as a therapeutic approach in SjD. - Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease.
Hiroyuki Nakamura; Tsutomu Tanaka; Youngmi Ji; Changyu Zheng; Sandra A Afione; Blake M Warner; Fabiola Reis Oliveira; Ana Carolina F Motta; Eduardo M Rocha; Masayuki Noguchi; Tatsuya Atsumi; John A Chiorini
PloS one, 18, 2, e0282227, 2023年, [国際誌]
英語, 研究論文(学術雑誌), Hydroxychloroquine (HCQ) is a lysosomotropic agent that is commonly used for treating Sjögren's disease (SjD). However, its efficacy is controversial because of the divergent response to the drug among patients. In a subgroup of SjD patients, lysosome-associated membrane protein 3 (LAMP3) is elevated in expression in the salivary glands and promotes lysosomal dysregulation and lysosome-dependent apoptotic cell death. In this study, chloroquine (CQ) and its derivative HCQ were tested for their ability to prevent LAMP3-induced apoptosis, in vitro and on a mouse model of SjD. In addition, efficacy of HCQ treatment was retrospectively compared between high LAMP3 mRNA expression in minor salivary glands and those with LAMP3 mRNA levels comparable with healthy controls. Study results show that CQ treatment stabilized the lysosomal membrane in LAMP3-overexpressing cells via deactivation of cathepsin B, resulting in decreased apoptotic cell death. In mice with established SjD-like phenotype, HCQ treatment also significantly decreased apoptotic cell death and ameliorated salivary gland hypofunction. Retrospective analysis of SjD patients found that HCQ tended to be more effective in improving disease activity index, symptom severity and hypergammaglobulinemia in patients with high LAMP3 expression compared those with normal LAMP3 expression. Taken together, these findings suggested that by determining salivary gland LAMP3 mRNA level, a patient's response to HCQ treatment could be predicted. This finding may provide a novel strategy for guiding the development of more personalized medicine for SjD. - Correction of LAMP3-associated salivary gland hypofunction by aquaporin gene therapy.
Hiroyuki Nakamura; Tsutomu Tanaka; Changyu Zheng; Sandra A Afione; Blake M Warner; Masayuki Noguchi; Tatsuya Atsumi; John A Chiorini
Scientific reports, 12, 1, 18570, 18570, 2022年11月03日, [国際誌]
英語, 研究論文(学術雑誌), Sjögren's disease (SjD) is a chronic autoimmune sialadenitis resulting in salivary gland hypofunction with dry mouth symptom. Previous studies showed that lysosome-associated membrane protein 3 (LAMP3) overexpression is involved in the development of salivary gland hypofunction associated with SjD. However, the molecular mechanisms are still unclear, and no effective treatment exists to reverse gland function in SjD. Analysis on salivary gland samples from SjD patients showed that salivary gland hypofunction was associated with decreased expression of sodium-potassium-chloride cotransporter-1 (NKCC1) and aquaporin 5 (AQP5), which are membrane proteins involved in salivation. Further studies revealed that LAMP3 overexpression decreased their expression levels by promoting endolysosomal degradation. Additionally, we found that LAMP3 overexpression enhanced gene transfer by increasing internalization of adeno-associated virus serotype 2 (AAV2) via the promoted endolysosomal pathway. Retrograde cannulation of AAV2 vectors encoding AQP1 gene (AAV2-AQP1) into salivary glands induced glandular AQP1 expression sufficient to restore salivary flow in LAMP3-overexpressing mice. LAMP3 could play a critical role in the development of salivary gland hypofunction in SjD by promoting endolysosomal degradation of NKCC1 and AQP5. But it also could enhance AAV2-mediated gene transfer to restore fluid movement through induction of AQP1 expression. These findings suggested that AAV2-AQP1 gene therapy is useful in reversing salivary gland function in SjD patients. - LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization.
Tsutomu Tanaka; Blake M Warner; Drew G Michael; Hiroyuki Nakamura; Toshio Odani; Hongen Yin; Tatsuya Atsumi; Masayuki Noguchi; John A Chiorini
Autophagy, 18, 7, 1629, 1647, 2022年07月, [国際誌]
英語, 研究論文(学術雑誌), A253-control: A253 control for LAMP3 stable overexpression; A253- LAMP3: A253 LAPM3 stable overexpression; CASP1: caspase 1; CASP3: caspase 3; CHX: cycloheximide; CTSB: cathepsin B; CTSD: cathepsin D; CQ: chloroquine; DCs: dendritic cells; ER: endoplasmic reticulum; LGALS3: galectin 3; HCV: hepatitis C virus; HSG-control: HSG control for LAMP3 stable overexpression; HSG-LAMP3: HSG LAMP3 stable overexpression; HSP: heat shock protein; HTLV-1: human T-lymphocyte leukemia virus-1; IXA: ixazomib; LAMP: lysosomal associated membrane protein; MHC: major histocompatibility complex; mAb: monoclonal antibody; OE: overexpression; pepA: pepstatin A; pAb: polyclonal antibody; pSS: primary Sjögren syndrome; qRT-PCR: quantitative real- time reverse transcriptase polymerase chain reaction; SLE: systemic lupus erythematosus; SS: Sjögren syndrome; UPR: unfolded protein response; V-ATPase: vacuolar-type proton- translocating ATPase; Y-VAD: Ac-YVAD-cmk; Z-DEVD; Z-DEVD-fmk; Z-VAD: Z-VAD- fmk. - Lysosomal exocytosis of HSP70 stimulates monocytic BMP6 expression in Sjögren's syndrome.
Ying-Qian Mo; Hiroyuki Nakamura; Tsutomu Tanaka; Toshio Odani; Paola Perez; Youngmi Ji; Benjamin N French; Thomas Jf Pranzatelli; Drew G Michael; Hongen Yin; Susan S Chow; Maryam Khalaj; Sandra A Afione; Changyu Zheng; Fabiola Reis Oliveira; Ana Carolina F Motta; Alfredo Ribeiro-Silva; Eduardo M Rocha; Cuong Q Nguyen; Masayuki Noguchi; Tatsuya Atsumi; Blake M Warner; John A Chiorini
The Journal of clinical investigation, 132, 6, 2022年03月15日, [国際誌]
英語, 研究論文(学術雑誌), BMP6 is a central cytokine in the induction of Sjögren's syndrome-associated (SS-associated) secretory hypofunction. However, the upstream initiation leading to the production of this cytokine in SS is unknown. In this study, RNA ISH on salivary gland sections taken from patients with SS indicated monocytic lineage cells as a cellular source of BMP6. RNA-Seq data on human salivary glands suggested that TLR4 signaling was an upstream regulator of BMP6, which was confirmed by in vitro cell assays and single-cell transcriptomics of human PBMCs. Further investigation showed that HSP70 was an endogenous natural TLR4 ligand that stimulated BMP6 expression in SS. Release of HSP70 from epithelial cells could be triggered by overexpression of lysosome-associated membrane protein 3 (LAMP3), a protein also associated with SS in several transcriptome studies. In vitro studies supported the idea that HSP70 was released as a result of lysosomal exocytosis initiated by LAMP3 expression, and reverse transcription PCR on RNA from minor salivary glands of patients with SS confirmed a positive correlation between BMP6 and LAMP3 expression. BMP6 expression could be experimentally induced in mice by overexpression of LAMP3, which developed an SS-like phenotype. The newly identified LAMP3/HSP70/BMP6 axis provided an etiological model for SS gland dysfunction and autoimmunity. - Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report.
Xinyu Weng; Daiju Iwata; Kenichi Namba; Kayo Suzuki; Kazuomi Mizuuchi; Hiroyuki Nakamura; Tatsuya Atsumi; Susumu Ishida
American journal of ophthalmology case reports, 25, 101333, 101333, 2022年03月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a necrotizing vasculitis syndrome characterized by the destruction of small vessels, leading to various organ disorders. Here, we report a case of posterior scleritis with AAV successfully treated with prednisolone and rituximab (RTX) combination therapy. OBSERVATIONS: A 69-year-old female suffered from ocular pain and redness in her left eye for 2.5 years. She had been diagnosed with idiopathic otitis media before a year. At her initial visit, scleral injection with nodular elevated scleral lesions, vitreous haze, and serous retinal detachment (SRD) in the inferior periphery were observed in the left eye. Enhanced computed tomography revealed the enhancement and thickening of the left sclera. The results of laboratory analysis were positive for myeloperoxidase ANCA. Accordingly, she was diagnosed with AAV. Owing to the exacerbation of vitreous haze and SRD, topical treatment and steroid pulse therapy were initiated. Following therapy, anterior and posterior scleritis improved, and additional RTX was administered to maintain the remission. Following treatment, the patient has maintained remission with 10 mg/day prednisolone to date. CONCLUSIONS AND IMPORTANCE: We encountered a case of posterior scleritis with AAV in which inflammatory manifestations subsided with RTX and glucocorticoid combination therapy. RTX administration likely contributed to the maintenance of remission. - Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren's syndrome-like phenotype in mice.
Hiroyuki Nakamura; Tsutomu Tanaka; Thomas Pranzatelli; Youngmi Ji; Hongen Yin; Paola Perez; Sandra A Afione; Shyh-Ing Jang; Corrine Goldsmith; Chang Yu Zheng; William D Swaim; Blake M Warner; Noriyuki Hirata; Masayuki Noguchi; Tatsuya Atsumi; John A Chiorini
Annals of the rheumatic diseases, 80, 8, 1031, 1039, 2021年08月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Sjögren's syndrome (SS) is an autoimmune sialadenitis with unknown aetiology. Although extensive research implicated an abnormal immune response associated with lymphocytes, an initiating event mediated by salivary gland epithelial cell (SGEC) abnormalities causing activation is poorly characterised. Transcriptome studies have suggested alternations in lysosomal function are associated with SS, but a cause and effect linkage has not been established. In this study, we demonstrated that altered lysosome activity in SGECs by expression of lysosome-associated membrane protein 3 (LAMP3) can initiate an autoimmune response with autoantibody production and salivary dysfunction similar to SS. METHODS: Retroductal cannulation of the submandibular salivary glands with an adeno-associated virus serotype 2 vector encoding LAMP3 was used to establish a model system. Pilocarpine-stimulated salivary flow and the presence of autoantibodies were assessed at several time points post-cannulation. Salivary glands from the mice were evaluated using RNAseq and histologically. RESULTS: Following LAMP3 expression, saliva flow was significantly decreased and serum anti-Ro/SSA and La/SSB antibodies could be detected in the treated mice. Mechanistically, LAMP3 expression increased apoptosis in SGECs and decreased protein expression related to saliva secretion. Analysis of RNAseq data suggested altered lysosomal function in the transduced SGECs, and that the cellular changes can chemoattract immune cells into the salivary glands. Immune cells were activated via toll-like receptors by damage-associated molecular patterns released from LAMP3-expressing SGECs. CONCLUSIONS: These results show a critical role for lysosomal trafficking in the development of SS and establish a causal relationship between LAMP3 misexpression and the development of SS. - How should rheumatologists manage glucocorticoid-induced hyperglycemia?
Hiroyuki Nakamura; Yuichiro Fujieda; Akinobu Nakamura; Tatsuya Atsumi
Modern rheumatology, 31, 3, 519, 528, 2021年05月, [国際誌]
英語, 研究論文(学術雑誌), Glucocorticoid-induced hyperglycemia (GIH) is an important complication to be managed by rheumatologists as it can affect morbidity and mortality of patients. Before administration of glucocorticoids, risk for the development of GIH should be assessed in every patient. A meta-analysis identified male gender, older age, family history of diabetes mellitus, current smoking history, past history of hypertension, higher body mass index, higher fasting plasma glucose (PG) and higher hemoglobin A1c (HbA1c) levels as risk factors for GIH. Then, rheumatologists need to carefully monitored PG levels including 2-h after meals because glucocorticoids particularly affect postprandial glucose metabolism. Fasting PG level ≥ 126 mg/dL and/or post-meal PG level ≥ 200 mg/dL are considered as GIH regardless of HbA1c level. Treatment strategy for GIH should center on insulin injection since the effectiveness of oral hypoglycemic agents for GIH has been uncertain. But, rheumatologists may try oral hypoglycemic agents in advance of insulin therapy for mild GIH, whereas diabetologists should be consulted in case of intractable GIH. More strict control of GIH could be possible using intensive insulin protocol. Rheumatologists are encouraged to be interested in the management of GIH for providing patients superior care, working closely with diabetologists. - LAMP3 induces apoptosis and autoantigen release in Sjögren's syndrome patients.
Tsutomu Tanaka; Blake M Warner; Toshio Odani; Youngmi Ji; Ying-Qian Mo; Hiroyuki Nakamura; Shyh-Ing Jang; Hongen Yin; Drew G Michael; Noriyuki Hirata; Futoshi Suizu; Satoko Ishigaki; Fabiola Reis Oliveira; Ana Carolina F Motta; Alfredo Ribeiro-Silva; Eduardo M Rocha; Tatsuya Atsumi; Masayuki Noguchi; John A Chiorini
Scientific reports, 10, 1, 15169, 15169, 2020年09月16日, [国際誌]
英語, 研究論文(学術雑誌), Primary Sjögren's syndrome (pSS) is a complex autoimmune disease characterized by dysfunction of secretory epithelia with only palliative therapy. Patients present with a constellation of symptoms, and the diversity of symptomatic presentation has made it difficult to understand the underlying disease mechanisms. In this study, aggregation of unbiased transcriptome profiling data sets of minor salivary gland biopsies from controls and Sjögren's syndrome patients identified increased expression of lysosome-associated membrane protein 3 (LAMP3/CD208/DC-LAMP) in a subset of Sjögren's syndrome cases. Stratification of patients based on their clinical characteristics suggested an association between increased LAMP3 expression and the presence of serum autoantibodies including anti-Ro/SSA, anti-La/SSB, anti-nuclear antibodies. In vitro studies demonstrated that LAMP3 expression induces epithelial cell dysfunction leading to apoptosis. Interestingly, LAMP3 expression resulted in the accumulation and release of intracellular TRIM21 (one component of SSA), La (SSB), and α-fodrin protein, common autoantigens in Sjögren's syndrome, via extracellular vesicles in an apoptosis-independent mechanism. This study defines a clear role for LAMP3 in the initiation of apoptosis and an independent pathway for the extracellular release of known autoantigens leading to the formation of autoantibodies associated with this disease.ClinicalTrials.gov Identifier: NCT00001196, NCT00001390, NCT02327884. - Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study.
Hiroyuki Nakamura; Yuichiro Fujieda; Masato Tarumi; Hirohiko Kitakawa; Ryo Hisada; Ikuma Nakagawa; Atsushi Noguchi; Takashi Kurita; Hiroshi Kataoka; Hideki Kasahara; Yoshiharu Amasaki; Isao Yokota; Tatsuya Atsumi
Clinical and experimental rheumatology, 38 Suppl 127, 5, 11, 16, 2020年, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: To clarify the efficacy and safety of calcineurin inhibitors (CNI) for treating adult-onset Still's disease (AOSD). METHODS: This multicentre historical cohort study enrolled the consecutive patients with AOSD according to Yamaguchi classification criteria. The endpoints were set as the time from the initiation of treatment to events, the persistency rate of CNI and safety. Based on the recurrent event data analysis, these endpoints were evaluated for each event. We divided the events into two groups according to the treatment that included CNI or conventional therapy without CNI. RESULTS: One hundred seventy-eight patients with 247 events were analysed. CNI were predominantly used in 72 events with a recurrent history, typical skin rash, high ferritin levels, and/or severe complications such as macrophage activation syndrome, disseminated intravascular coagulation, serositis, meningitis. CNI led to a significantly longer event-free survival (hazard ratio: 0.57, 95% confidential interval: 0.32-0.99) after adjustment of concomitant medications. Subgroup analysis showed that CNI were effective for AOSD patients with high ALT level (hazard ratio: 0.11, 95% confidential interval: 0.02-0.59) and severe complications (hazard ratio: 0.11, 95% confidential interval: 0.01-0.94). The persistency rate of CNI was 71% at 5th year. Adverse events occurred more frequently in the CNI group (18% versus 8%, p=0.02); however, CNI did not involve in increased risk of adverse events, including nephrotoxicity, after adjustment (p=0.23). CONCLUSIONS: Our retrospective analysis suggested that CNI could be an effective and safe option for treating AOSD. - Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.
Keita Ninagawa; Masaru Kato; Hiroyuki Nakamura; Nobuya Abe; Michihito Kono; Yuichiro Fujieda; Kenji Oku; Shinsuke Yasuda; Hiroshi Ohira; Ichizo Tsujino; Tatsuya Atsumi
Rheumatology international, 39, 11, 1883, 1887, 2019年11月, [国際誌]
英語, 研究論文(学術雑誌), Early intervention in pulmonary arterial hypertension associated with systemic sclerosis (SSc) may improve its prognosis. We aimed to establish an algorithm to detect mean pulmonary artery pressure (mPAP) > 20 mmHg using non-invasive examinations in SSc patients by modifying the DETECT algorithm. This study included SSc patients who underwent right heart catheterization (RHC) in our hospital during 2010-2018. Following variables were assessed for performance to predict mPAP ≥ 25 mmHg or > 20 mmHg; anti-centromere or U1-RNP antibody, plasma BNP level, serum urate level, right axis deviation, forced vital capacity (FVC)/diffusing capacity for carbon monoxide (DLCO) ratio, and tricuspid regurgitation velocity. Of 58 patients enrolled in this study, 24 had mPAP of ≥ 25 mmHg and 9 had mPAP of 21-24 mmHg. Among variables tested, only FVC/DLCO elevated similarly in patients with mPAP of ≥ 25 mmHg (median 2.5) and those with mPAP of 21-24 mmHg (median 2.5) compared to those with mPAP of ≤ 20 mmHg (median 1.5). Given the particularly good correlation between DLCO and mPAP of > 20 mmHg, each variable was weighted according to its odds ratio and the total weighted score was calculated. The total weighted score exhibited a good predictive performance for mPAP of > 20 mmHg with its sensitivity of 87.5% and specificity of 92%. Among conventional risk factors for PAH, decreased DLCO may predict mPAP > 20 mmHg with priority in SSc patients. Weighting DLCO may improve the performance of screening algorithm for early SSc-PAH. - Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome.
Naoki Ohnishi; Yuichiro Fujieda; Ryo Hisada; Hiroyuki Nakamura; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Tatsuya Atsumi
Rheumatology (Oxford, England), 58, 6, 969, 974, 2019年06月01日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Warfarin is regarded as the standard treatment for preventing thrombotic events in APS, but the recurrence rate is still high. Dual antiplatelet therapy (DAPT) has been shown to be effective for the prevention of acute coronary syndrome or stroke. The objective of this study was to evaluate the efficacy of DAPT for the prevention of thrombosis recurrence in APS patients with history of arterial thrombosis. METHODS: This retrospective cohort study of APS patients was conducted at Hokkaido University Hospital between 1990 and 2016. The secondary prophylactic effects and safety of warfarin monotherapy (Wf), antiplatelet monotherapy (AP), warfarin and antiplatelet combination therapy (Wf + AP) and DAPT were evaluated. The primary endpoints were set as thrombosis-free and adverse events-free survival period. Adverse events were defined as severe bleeding and death. RESULTS: A total of 90 APS patients were enrolled. Thrombotic recurrence was found in 40 patients (35 arterial and 5 venous thromboses) and serious adverse events in 20 patients (9 severe bleeding events and 14 deaths). Kaplan-Meier analysis demonstrated a 10-year recurrence-free survival rate of 62%. The recurrence rate per 100 patient-years was as follows: Wf: 11.6, AP: 5.5, Wf: + AP: 3.7, DAPT: 1.8. We demonstrated that DAPT significantly reduced the rate of recurrence compared with Wf (log-rank P = 0.001). There were no significant differences in the rate of serious adverse events among the groups. CONCLUSION: DAPT might be considered as an effective and safe option for the prophylaxis of recurrent arterial thrombosis in APS. - Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis.
Hiroyuki Nakamura; Sanae Shimamura; Shinsuke Yasuda; Michihito Kono; Michihiro Kono; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Tomohiro Shimizu; Norimasa Iwasaki; Tatsuya Atsumi
Annals of the rheumatic diseases, 77, 12, 1765, 1772, 2018年12月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune polyarthritis, in which fibroblast-like synoviocytes (FLS) play a key role in cartilage and bone destruction through tumour-like proliferation and invasiveness. Considering still unsatisfactory remission rate in RA even under treatment with biological disease-modifying antirheumatic drugs, novel therapeutic strategy for treatment-resistant RA is still awaited. In this study, we analysed the expression and function of Ras guanine nucleotide-releasing proteins (RASGRPs), guanine exchange factors for small GTPase Ras, in FLS as a potential therapeutic target for RA. METHODS: The expression of RASGRPs mRNA was quantified by a real-time PCR assay in FLS isolated from synovial tissue samples. RASGRP2 protein was also evaluated immunohistochemically. Then, we transiently transfected FLS with RASGRP2 expression vector and assessed their proliferation, adhesion, migration and invasion by cellular functional assays and downstream signalling activation using immunoblot. Finally, the therapeutic effect of RASGRP2 silencing was evaluated in type-II collagen-induced arthritis rats. RESULTS: RASGRP2 was abundantly expressed in FLS from RA synovium, whereas scarcely found in those from osteoarthritis. Expression of RASGRP2 in RA-FLS was enhanced by transforming growth factor-beta. RASGRP2 activated RAP-1, subsequently affecting nuclear factor kappa-light-chain-enhancer of activated B cells pathway and actin dynamics in FLS. RASGRP2-overexpressed FLS had increased abilities of adhesion, migration and interleukin (IL)-6 production. Silencing of RASGRP2 using the intra-articular injection of Rasgrp2-specific siRNAs dampened experimental arthritis in rats by inhibiting pannus formation. CONCLUSIONS: RASGRP2 was identified to be involved in the pathogenesis of RA by promoting adhesion, migration and IL-6 production from FLS, proposed as a potential novel non-immunosuppressive therapeutic target for RA. - Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
Hiroyuki Nakamura; Yuichiro Fujieda; Shinsuke Yasuda; Masato Nakai; Tatsuya Atsumi
Annals of internal medicine, 169, 5, 352, 353, 2018年09月04日, [国際誌]
英語 - Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus.
Shun Tanimura; Yuichiro Fujieda; Michihiro Kono; Yuhei Shibata; Ryo Hisada; Eri Sugawara; Hiroyuki Nakamura; Kazumasa Ohmura; Sanae Shimamura; Asako Mitani; Haruki Shida; Toshiyuki Watanabe; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Chikara Shimizu; Tatsuya Atsumi
Modern rheumatology, 28, 5, 865, 871, 2018年09月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Presepsin (PSEP: soluble CD14 subtype) is produced from bacteria-stimulated monocytes or neutrophils, thus recognized as a biomarker of sepsis. Aberrant functions in monocyte or neutrophils are increasingly recognized in systemic lupus erythematosus (SLE). We investigated whether plasma PSEP reflects disease activity in patients with SLE. METHODS: This retrospective study comprised 35 patients with SLE and 72 with non-SLE autoimmune diseases who visited our facility during the period from August 2012 to September 2015. Plasma PSEP levels and laboratory data were compared between SLE and non-SLE. Clinical markers of SLE disease activity, including SLE disease activity index 2000 (SLEDAI-2K), serum complement concentrations and serum anti-ds-DNA antibodies were assessed in correlation with plasma PSEP levels. RESULTS: Plasma PSEP levels in SLE were higher than those in non-SLE. This phenomenon holds true when comparing SLE and non-SLE patients in the absence of infection (p = .0008). Plasma PSEP levels in SLE patients negatively correlated with C3 (r = -0.4454, p = .0430), CH50 (r = -0.4502, p = .0406) and positively with SLEDAI-2K (r = 0.4801, p = .0237). CONCLUSION: Elevated plasma PSEP levels were correlated with disease activity of SLE, suggesting inappropriate monocyte or neutrophil activation in the pathophysiology of SLE exacerbation. - Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy.
Hiroyuki Nakamura; Toshio Odani; Shinsuke Yasuda; Atsushi Noguchi; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Junichi Sugita; Tomoyuki Endo; Takanori Teshima; Tatsuya Atsumi
Modern rheumatology, 28, 5, 879, 884, 2018年09月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: The objective of this study is to elucidate the efficacy and safety of autologous haematopoietic stem cell transplantation (HSCT) for Japanese patients with systemic sclerosis (SSc). METHODS: A phase II clinical trial included SSc patients diagnosed within the last three years having at least one of the following clinical features: diffuse skin sclerosis with modified Rodman total thickness skin score (mRSS) ≥ 15, refractory digital ulcer or interstitial lung disease (ILD). HSCT were performed after conditioning using cyclophosphamide. RESULTS: Fourteen patients were enrolled and underwent HSCT. Median follow-up period was 137 months. Overall survival or event-free survival rate was 93% or 40% at 10 years, respectively. Eight patients (57%) achieved more than a 50% decrease in mRSS from baseline within six months after HSCT. Six patients (43%) required additional immunosuppressive treatments due to progression of diffuse skin sclerosis and/or ILD during follow-up period. Adverse events related to HSCT occurred in six patients (43%). Severe cardiomyopathy occurred in two patients, and one of them had a fatal course. CONCLUSION: HSCT is a feasible treatment bringing favourable results to more than half of our patients with SSc. Careful selection of the patients is essential for whom benefited from HSCT, considering the risk-benefit balance of the treatment. - First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β2 -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies Tests.
Hiroyuki Nakamura; Kenji Oku; Olga Amengual; Kazumasa Ohmura; Yuichiro Fujieda; Masaru Kato; Toshiyuki Bohgaki; Shinsuke Yasuda; Tatsuya Atsumi
Arthritis care & research, 70, 4, 627, 634, 2018年04月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: To assess the value of a combination of anti-β2 -glycoprotein I (anti-β2 GPI) domain I antibody and anti-phosphatidylserine/prothrombin complex (anti-PS/PT) antibody tests for the diagnosis of antiphospholipid syndrome (APS). METHODS: This cross-sectional study involved a cohort of the patients who visited our clinic from April 2005 to March 2013. Tests for anti-β2 GPI domain I antibodies, IgG anti-PS/PT antibodies, and IgM anti-PS/PT antibodies, together with tests for criteria-defined antiphospholipid antibodies (aPL), were performed in all patients. The total antiphospholipid score (aPL-S) was calculated for each patient according to titers of and positivity for aPL. RESULTS: The study enrolled 157 patients (51 patients with APS and 106 with non-APS autoimmune diseases). All 21 patients positive for both anti-β2 GPI domain I antibodies and IgG and/or IgM (IgG/IgM) anti-PS/PT antibodies had APS with a high total aPL-S (median 46, range 26-76), as did all of the 10 patients who were positive for anti-β2 GPI domain I antibodies but negative for IgG/IgM anti-PS/PT antibodies (median 22, range 4-39). Of the 14 patients who were positive for IgG/IgM anti-PS/PT antibodies but negative for anti-β2 GPI domain I antibodies, 11 (79%) had APS; these individuals also had high total aPL-S values (median 23, range 11-60). In contrast, only 9 of the 112 patients (8%) with none of these antibodies had APS. CONCLUSION: The combination of the IgG anti-β2 GPI domain I antibody and IgG/IgM anti-PS/PT antibody tests shows a high positive predictive value for the diagnosis of APS and a strong correlation with the aPL-S. This combination as the first-line test for aPL may contribute to the simple and definite identification of APS with a high risk of thrombosis in clinical practice. - Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome.
Hiroyuki Nakamura; Kenji Oku; Yusuke Ogata; Kazumasa Ohmura; Yoko Yoshida; Etsuko Kitano; Yuichiro Fujieda; Masaru Kato; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Yoshihiro Fujimura; Tsukasa Seya; Tatsuya Atsumi
Thrombosis research, 164, 63, 68, 2018年04月, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Although complement activation has been proposed as a possible thrombophilic mechanism in antiphospholipid syndrome (APS), the origin of complement activation in APS remains unclear. Here, we focused on complement regulatory factors (CRF), which control the complement system to prevent damage to host tissue. We evaluated the function of two major CRF, membrane cofactor protein (MCP) and factor H (FH), in APS patients. MATERIALS AND METHODS: In this study, we analyzed preserved serum samples from 27 patients with primary APS (PAPS), 20 with APS complicated with SLE (APS + SLE), 24 with SLE (SLE), and 25 with other connective tissue diseases (Other CTD). Serum MCP and FH levels were tested by ELISA. Autoantibodies against FH were determined by both ELISA and western-blotting. RESULTS: Serum complement levels of PAPS were lower than those of other CTD (median C3: 82 vs 112 mg/dL, p < 0.01, C4: 15 vs 22 mg/dL, p < 0.05). Serum MCP levels did not significantly differ among the groups. Serum FH levels were significantly lower in PAPS patients compared with SLE or other CTD (median 204, 1275, and 1220 μg/mL, respectively, p < 0.01). In PAPS patients, serum FH levels were positively correlated with serum C3 levels (p < 0.01, R = 0.55), but no correlation was found with serum C4 levels (p = 0.22, R = 0.33). Autoantibodies against FH were not detected in any of our patients. CONCLUSIONS: Activation of the alternative complement pathway due to low level of FH is one of the possible thrombophilic mechanisms in PAPS. - Efficient detection of pulmonary arterial hypertension using serum haptoglobin level and cardiac MRI in patients with connective tissue diseases: a pilot study.
Hiroyuki Nakamura; Masaru Kato; Atsushi Nogochi; Hiroshi Ohira; Ichizo Tsujino; Tatsuya Atsumi
Clinical and experimental rheumatology, 36, 2, 345, 346, 2018年, [国際誌]
英語, 研究論文(学術雑誌) - Kasabach-Merritt phenomenon with concurrent appearance of antiphospholipid antibodies in a patient with giant liver haemangioma.
Hiroyuki Nakamura; Yuichiro Fujieda; Masaru Kato; Tatsuya Atsumi
Rheumatology advances in practice, 2, 2, rky047, 2018年, [国際誌]
英語, 研究論文(学術雑誌) - Decreased haptoglobin levels inversely correlated with pulmonary artery pressure in patients with pulmonary arterial hypertension: A cross-sectional study.
Hiroyuki Nakamura; Masaru Kato; Toshitaka Nakaya; Michihiro Kono; Shun Tanimura; Takahiro Sato; Yuichiro Fujieda; Kenji Oku; Hiroshi Ohira; Toshiyuki Bohgaki; Shinsuke Yasuda; Ichizo Tsujino; Masaharu Nishimura; Tatsuya Atsumi
Medicine, 96, 43, e8349, 2017年10月, [国際誌]
英語, 研究論文(学術雑誌), We investigated the serum haptoglobin levels in patients with pulmonary arterial hypertension (PAH) based on the hypothesis that haptoglobin levels would reflect subclinical hemolysis due to microangiopathy in pulmonary arterioles.This cross-sectional study included 3 groups of patients attending Hokkaido University Hospital: PAH, chronic thromboembolic pulmonary hypertension (CTEPH), and connective tissue diseases (CTD) without PAH (CTD-non-PAH) group. Serum haptoglobin levels were measured by standardized turbidimetric immunoassay in all patients. Demographic data, laboratory results, right heart catheter, and echocardiographic findings were extracted from the medical records. Decreased haptoglobin levels were defined as below 19 mg/dL based on the 95th percentile of healthy controls.Thirty-five patients in PAH group including 11 with idiopathic PAH (IPAH) and 24 with CTD-associated PAH (CTD-PAH), 27 in CTEPH group, and 32 in CTD-non-PAH group were analyzed. Serum haptoglobin levels in PAH group (median 66 mg/dL) were significantly lower than those in CTEPH group (median 94 mg/dL, P = .03) and CTD-non-PAH group (median 79 mg/dL, P = .03). The prevalence of decreased haptoglobin levels was 26% in PAH group, 15% in CTEPH group, and 6% in CTD-non-PAH group. Serum haptoglobin levels had a significant negative correlation (r = -0.66, P < .001) with mean pulmonary artery pressure in PAH group, particularly in CTD-PAH subgroup (r = -0.74, P < .001), but no correlation in IPAH subgroup (r = -0.52, P = .13) and in CTEPH group (r = -0.17, P = .41). Follow-up cases of CTD-PAH showed lowering pulmonary artery pressure led to normalizing serum haptoglobin levels.Serum haptoglobin levels decreased in PAH patients and inversely correlated with pulmonary artery pressure in CTD-PAH patients, suggesting their potential as a surrogate marker for CTD-PAH. - Unusual tense bullae on the legs of a woman with rheumatoid arthritis.
Hideyuki Kosumi; Teruki Yanagi; Keiko Shiba; Tatsuro Sugai; Hiroyuki Nakamura; Hiroshi Shimizu
Rheumatology (Oxford, England), 56, 9, 1471, 1471, 2017年09月01日, [国際誌]
英語, 研究論文(学術雑誌) - Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
Hiroyuki Nakamura; Tatsuro Sugai; Masaru Kato; Kanako C Hatanaka; Tatsuya Atsumi
Clinical and experimental rheumatology, 35, 1, 174, 174, 2017年, [国際誌]
英語 - Complement and thrombosis in the antiphospholipid syndrome.
Kenji Oku; Hiroyuki Nakamura; Michihiro Kono; Kazumasa Ohmura; Masaru Kato; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Olga Amengual; Tatsuya Atsumi
Autoimmunity reviews, 15, 10, 1001, 4, 2016年10月, [国際誌]
英語, 研究論文(学術雑誌), The involvement of complement activation in the pathophysiology of antiphospholipid syndrome (APS) was first reported in murine models of antiphospholipid antibody (aPL)-related pregnancy morbidities. We previously reported that complement activation is prevalent and may function as a source of procoagulant cell activation in the sera of APS patients. Recently, autoantibodies against C1q, a component of complement 1, were reported to be correlated with complement activation in systemic lupus erythematosus. These antibodies target neoepitopes of deformed C1q bound to various molecules (i.e., anionic phospholipids) and induce accelerated complement activation. We found that anti-C1q antibodies are more frequently detected in primary APS patients than in control patients and in refractory APS patients with repeated thrombotic events. The titer of anti-C1q antibodies was significantly higher in refractory APS patients than in APS patients without flare. The binding of C1q to anionic phospholipids may be associated with the surge in complement activation in patients with anti-C1q antibodies when triggered by 'second-hit' biological stressors such as infection. Such stressors will induce overexpression of anionic phospholipids, with subsequent increases in deformed C1q that is targeted by anti-C1q antibodies.
- Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation
Hiroyuki Nakamura; Shinsuke Yasuda; Atsushi Noguchi; Toshio Odani; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Junichi Sugita; Toshiyuki Bohgaki; Tomoyuki Endo; Takanori Teshima; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 69, 2017年10月
英語, 研究発表ペーパー・要旨(国際会議) - Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura; Kenji Oku; Ryo Hisada; Kazumasa Ohmura; Masaru Kato; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Kenji Oku; Uhei Shibata; Joana Batuca; Olga Amengual; Michihiro Kono; Hiroyuki Nakamura; Ryo Hisada; Kazumasa Ohmura; Masaru Kato; Toshiyuki Bohgaki; Shinsuke Yasuda; Jose Delgado Alves; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議)
- シェーグレン症候群の腺外病変発症におけるHPV感染の関与と2型IFN応答
科学研究費助成事業
2025年04月01日 - 2030年03月31日
中村 浩之
日本学術振興会, 若手研究, 札幌医科大学, 25K19597 - オミクス解析から紐解くシェーグレン症候群の疾患多様性解明
科学研究費助成事業
2025年04月01日 - 2030年03月31日
皆木 瞳; 中村 浩之; 阪井 丘芳
日本学術振興会, 基盤研究(B), 大阪大学, 25K02823 - 唾液腺上皮の異所性LAMP3発現が全身性自己免疫疾患の発症に及ぼす影響
科学研究費助成事業
2023年08月31日 - 2025年03月31日
中村 浩之
先行研究において研究者らは、ウイルスに対する過剰な1型インターフェロン応答の結果、シェーグレン症候群患者の唾液腺上皮細胞にlysosome-associated membrane protein 3 (LAMP3) が異所性発現し、唾液腺上皮細胞のアポトーシスやダメージ関連分子パターンの放出を促進することが明らかとした。
本研究ではさらに、唾液腺上皮細胞にLAMP3を強制発現させたとき1型インターフェロンであるIFNαとIFNβの発現が亢進することを明らかにした。一方で、IL-1、IL-6、TNF-αなどの炎症性サイトカインやCCL3、CCL4、CCL5、CX3CL1などのケモカインの産生増加は認めなかった。またLAMP3を強制発現させた唾液腺上皮細胞では、TLR7の異所性発現が誘導されており、マウスの唾液腺にLAMP3を過剰発現させた動物実験においても同様のTLR7の異所性発現が確認された。またLAMP3を過剰発現させたマウスの唾液腺では1型インターフェロン応答が増強しているが、それはTLR7のノックアウトによって是正された。すなわちLAMP3はTLR7の発現誘導を介して唾液腺上皮細胞の1型インターフェロン産生を促進していると考えられた。
さらにLAMP3発現唾液腺上皮細胞の培養上清で単球系細胞株のTHP-1を刺激したとき、THP-1のIFNβ発現が亢進がした。一方でTHP-1をTLR4シグナルの阻害剤であるTAK-242で前処理したときIFNβの発現亢進は生じなかった。そのためLAMP3発現唾液腺上皮細胞は、TLR4アゴニストとなりうるダメージ関連分子パターンの放出を介して、単球のIFNβ産生を促進していると考えられた。
以上から唾液腺上皮の異所性LAMP3発現は1型インターフェロン産生を増幅し、全身性自己免疫疾患の発症に寄与していると考えた。
日本学術振興会, 研究活動スタート支援, 札幌医科大学, 23K19486
